HK1209344A1 - Truncated analogues of glucose-dependent insulinotropic polypeptide - Google Patents
Truncated analogues of glucose-dependent insulinotropic polypeptideInfo
- Publication number
- HK1209344A1 HK1209344A1 HK15110126.9A HK15110126A HK1209344A1 HK 1209344 A1 HK1209344 A1 HK 1209344A1 HK 15110126 A HK15110126 A HK 15110126A HK 1209344 A1 HK1209344 A1 HK 1209344A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glucose
- dependent insulinotropic
- insulinotropic polypeptide
- truncated analogues
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18819208P | 2008-08-07 | 2008-08-07 | |
US20062808P | 2008-12-02 | 2008-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209344A1 true HK1209344A1 (en) | 2016-04-01 |
Family
ID=41664127
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11109018.6A HK1154787A1 (en) | 2008-08-07 | 2011-08-26 | Truncated analogues of glucose-dependent insulinotropic polypeptide |
HK15110126.9A HK1209344A1 (en) | 2008-08-07 | 2011-08-26 | Truncated analogues of glucose-dependent insulinotropic polypeptide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11109018.6A HK1154787A1 (en) | 2008-08-07 | 2011-08-26 | Truncated analogues of glucose-dependent insulinotropic polypeptide |
Country Status (16)
Country | Link |
---|---|
US (1) | US8450266B2 (xx) |
EP (2) | EP2320923B1 (xx) |
JP (2) | JP2011530506A (xx) |
KR (2) | KR101419332B1 (xx) |
CN (2) | CN102170896A (xx) |
AU (1) | AU2009280012B2 (xx) |
BR (1) | BRPI0917001A2 (xx) |
CA (1) | CA2733005C (xx) |
DK (1) | DK2320923T3 (xx) |
EA (1) | EA020018B1 (xx) |
ES (1) | ES2528599T3 (xx) |
HK (2) | HK1154787A1 (xx) |
MX (1) | MX2011001028A (xx) |
PL (1) | PL2320923T3 (xx) |
PT (1) | PT2320923E (xx) |
WO (1) | WO2010016935A2 (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011001031A (es) | 2008-08-07 | 2011-04-26 | Ipsen Pharma Sas | Analogos de polipeptidos insulinotropicos dependientes de glucosa. |
EP2323678B1 (en) | 2008-08-07 | 2016-03-23 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
DK2320923T3 (en) | 2008-08-07 | 2015-03-02 | Ipsen Pharma Sas | Truncated analogues of glucose-dependent insulinotropic polypeptide |
DK2549276T3 (en) * | 2009-08-10 | 2015-06-08 | Ucl Business Plc | Reversible, covalent bonding of functional molecules |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
WO2012168464A1 (en) * | 2011-06-10 | 2012-12-13 | Universität Bern | Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof |
KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3189072B1 (en) | 2014-09-05 | 2018-07-18 | University of Copenhagen | Gip peptide analogues |
SG11201805255TA (en) | 2015-12-23 | 2018-07-30 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
JP2020521784A (ja) | 2017-05-31 | 2020-07-27 | ユニバーシティ オブ コペンハーゲン | 長時間作用性gipペプチド類似体 |
ES2961384T3 (es) | 2018-05-04 | 2024-03-11 | Novo Nordisk As | Derivados de GIP y usos de los mismos |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US6905550B2 (en) * | 1996-05-06 | 2005-06-14 | Princeton Trade & Technology, Inc. | Method of removing organic materials using aqueous cleaning solutions |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
WO1998024464A1 (en) * | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
US7091183B1 (en) * | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
WO1999038536A1 (en) | 1998-01-29 | 1999-08-05 | Poly-Med Inc. | Absorbable microparticles |
WO2000004916A1 (en) | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
PL202367B1 (pl) * | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
US20040048248A1 (en) * | 1999-10-05 | 2004-03-11 | Prayaga Sudhirdas K. | Endozepine-like polypeptides and polynucleotides encoding same |
JP4455813B2 (ja) * | 2001-04-06 | 2010-04-21 | カリフォルニア インスティテュート オブ テクノロジー | 2つの溶液間の相互作用を促進するための方法 |
TWI284539B (en) * | 2001-07-30 | 2007-08-01 | Epix Pharm Inc | A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide |
PL208712B1 (pl) * | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
US20030232761A1 (en) * | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
WO2003105760A2 (en) * | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip) |
AU2003300139B2 (en) * | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
US7259234B2 (en) * | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
EA011653B1 (ru) * | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Аналоги и гибридные полипептиды gip с избираемыми свойствами |
US20090286724A1 (en) * | 2005-10-26 | 2009-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aggregable glp-1 analogue and sustained-release pharmaceutical composition |
AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
DK2320923T3 (en) | 2008-08-07 | 2015-03-02 | Ipsen Pharma Sas | Truncated analogues of glucose-dependent insulinotropic polypeptide |
-
2009
- 2009-08-07 DK DK09805288T patent/DK2320923T3/en active
- 2009-08-07 EP EP09805288.9A patent/EP2320923B1/en active Active
- 2009-08-07 WO PCT/US2009/004543 patent/WO2010016935A2/en active Application Filing
- 2009-08-07 US US13/057,864 patent/US8450266B2/en not_active Expired - Fee Related
- 2009-08-07 KR KR1020137020248A patent/KR101419332B1/ko not_active IP Right Cessation
- 2009-08-07 CA CA2733005A patent/CA2733005C/en not_active Expired - Fee Related
- 2009-08-07 PL PL09805288T patent/PL2320923T3/pl unknown
- 2009-08-07 KR KR1020117003754A patent/KR20110043687A/ko active Application Filing
- 2009-08-07 AU AU2009280012A patent/AU2009280012B2/en not_active Ceased
- 2009-08-07 MX MX2011001028A patent/MX2011001028A/es active IP Right Grant
- 2009-08-07 EP EP14194038.7A patent/EP2915538A3/en not_active Withdrawn
- 2009-08-07 BR BRPI0917001A patent/BRPI0917001A2/pt not_active Application Discontinuation
- 2009-08-07 CN CN2009801394614A patent/CN102170896A/zh active Pending
- 2009-08-07 ES ES09805288.9T patent/ES2528599T3/es active Active
- 2009-08-07 JP JP2011522068A patent/JP2011530506A/ja active Pending
- 2009-08-07 EA EA201170302A patent/EA020018B1/ru not_active IP Right Cessation
- 2009-08-07 CN CN201410230537.7A patent/CN104031140B/zh not_active Expired - Fee Related
- 2009-08-07 PT PT98052889T patent/PT2320923E/pt unknown
-
2011
- 2011-08-26 HK HK11109018.6A patent/HK1154787A1/xx not_active IP Right Cessation
- 2011-08-26 HK HK15110126.9A patent/HK1209344A1/xx unknown
-
2013
- 2013-10-04 JP JP2013209293A patent/JP5864506B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PL2320923T3 (pl) | 2015-06-30 |
US8450266B2 (en) | 2013-05-28 |
CN104031140A (zh) | 2014-09-10 |
KR101419332B1 (ko) | 2014-07-15 |
EP2915538A3 (en) | 2015-10-14 |
EA201170302A1 (ru) | 2011-10-31 |
EP2320923A2 (en) | 2011-05-18 |
HK1154787A1 (en) | 2012-05-04 |
WO2010016935A2 (en) | 2010-02-11 |
CN102170896A (zh) | 2011-08-31 |
AU2009280012A1 (en) | 2010-02-11 |
ES2528599T3 (es) | 2015-02-10 |
CA2733005C (en) | 2016-09-27 |
EP2915538A2 (en) | 2015-09-09 |
CN104031140B (zh) | 2017-04-12 |
JP5864506B2 (ja) | 2016-02-17 |
KR20130093693A (ko) | 2013-08-22 |
WO2010016935A3 (en) | 2010-04-08 |
EA020018B1 (ru) | 2014-08-29 |
EP2320923A4 (en) | 2012-07-18 |
PT2320923E (pt) | 2015-02-24 |
CA2733005A1 (en) | 2010-02-11 |
DK2320923T3 (en) | 2015-03-02 |
MX2011001028A (es) | 2011-04-26 |
US20110136724A1 (en) | 2011-06-09 |
KR20110043687A (ko) | 2011-04-27 |
AU2009280012B2 (en) | 2012-12-06 |
BRPI0917001A2 (pt) | 2016-02-16 |
EP2320923B1 (en) | 2014-12-24 |
JP2011530506A (ja) | 2011-12-22 |
JP2014051505A (ja) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2328922A4 (en) | ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE | |
HK1154787A1 (en) | Truncated analogues of glucose-dependent insulinotropic polypeptide | |
HK1154790A1 (zh) | 葡萄糖依賴性促胰島素多肽類似物 | |
EP2318433A4 (en) | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES (GIP) MODIFIED AT THE N-TERMINAL END | |
HK1203531A1 (en) | Glucagon analogues | |
IL218751A0 (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | |
ZA201104592B (en) | Glucagon analogues | |
ZA201104593B (en) | Glucagon analogues | |
ZA201104591B (en) | Glucagon analogues | |
EP2479193A4 (en) | INSULINOTROPIC PEPTIDE ANALOGUE HOMODIMER, METHOD FOR PREPARING SAME, AND USES THEREOF | |
HK1170941A1 (en) | Oxyntomodulin peptide analogue | |
HK1170943A1 (en) | Oxyntomodulin peptide analogue | |
EP2348049A4 (en) | NEW APPLICATION OF AIMP1 POLYPEPTIDE | |
ZA201201259B (en) | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses | |
GB0917072D0 (en) | Peptide analogues of glucagon for diabetes therapy | |
EP2480578A4 (en) | MODIFICATION OF POLYPEPTIDE | |
HK1220701A1 (zh) | 胰島素樣肽 | |
IL205971A0 (en) | Delivery of functional compounds | |
EP2270141A4 (en) | Lacritin PART PEPTIDE | |
ZA201007911B (en) | Processes for refolding of insulin | |
EP2478010A4 (en) | PART PEPTIDE OF LACRITINE | |
GB0913228D0 (en) | Loading element | |
HK1156630A1 (en) | Schweinfurthin analogues schweinfurthin | |
EP2450036A4 (en) | SURFACE ANESTHETIC AGENTS | |
GB0821979D0 (en) | Use of variant interferon alpha |